Business UpdateJun 11, 2026, 07:21 AM
AC Immune Receives $4M Grant for Parkinson's Trial Extension
AI Summary
AC Immune SA announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. This grant will fund the extension of Part 1 of the ongoing Phase 2 VacSYn trial for ACI-7104, an active immunotherapy for early Parkinson's disease. The extension will assess the long-term safety and efficacy of the treatment for an additional two years. Final data from Part 1 are anticipated in the second half of 2026. Previous interim results from December 2025 indicated a potential disease-modifying effect and a favorable safety profile.
Key Highlights
- AC Immune receives $4 million research grant from The Vijay and Marie Goradia Charitable Foundation.
- Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 for an additional 2 years.
- The extension will assess long-term safety and efficacy of ACI-7104 in early Parkinson's disease.
- Final data from Part 1 of the VacSYn trial are expected in H2 2026.
- Positive interim results from the Phase 2 VacSYn trial were reported in December 2025, suggesting a potential disease-modifying effect for ACI-7104.
Price Impact
More from ACIU